Serum levels of tissue inhibitor of metalloproteinase-1 are correlated with liver fibrosis in patients with chronic hepatitis B

Journal of Digestive Diseases

Volumn 13, Issue 11, 2012, Pages 558-563

  Zhu, Chuan Long ^a   Li, Wen Ting ^a   Li, Yi ^a   Gao, Ren Tao ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Chronic; Fibrosis; Hepatitis B; Tissue inhibitor of metalloproteinases 1

Indexed keywords

COLLAGEN TYPE 4; HYALURONIC ACID; LAMININ; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIB 4 INDEX; HEPATITIS B; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BIOPSY; COLLAGEN TYPE III; COLLAGEN TYPE IV; DISEASE PROGRESSION; FEMALE; HEPATITIS B, CHRONIC; HUMANS; HYALURONIC ACID; LAMININ; LIVER CIRRHOSIS; MALE; MIDDLE AGED; ROC CURVE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; YOUNG ADULT;

EID: 84868089561     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2012.00629.x     Document Type: Article

References (33)

1. World Health Organization. Hepatitis B. Fact sheet no. 204 (Revised August 2008). Cited 29 Nov 2011. Available from URL: http://www.who.int/mediacentre/factsheets/fs204/en/
2. Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol 2009; 51: 403-410.
3. Fallowfield JA. Therapeutic targets in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2011; 300: G709-715.
4. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500.
5. Sterling RK, Lissen E, Clumeck N etal; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325.
6. Forns X, Ampurdanès S, Llovet JM etal. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-992.
7. Rosenberg WM, Voelker M, Thiel R etal; European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-1713.
8. Zeng MD, Lu LG, Mao YM etal. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005; 42: 1437-1445.
9. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218.
10. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003; 38 Suppl 1: S38-53.
11. Murawaki Y, Ikuta Y, Idobe Y, Kitamura Y, Kawasaki H. Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease. J Hepatol 1997; 26: 1213-1219.
12. Benyon RC, Iredale JP, Goddard S, Winwood PJ, Arthur MJ. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 1996; 110: 821-831.
13. Herbst H, Wege T, Milani S etal. Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis. Am J Pathol 1997; 150: 1647-1659.
14. Yoshiji H, Kuriyama S, Miyamoto Y etal. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 2000; 32: 1248-1254.
15. Nie QH, Cheng YQ, Xie YM, Zhou YX, Cao YZ. Inhibiting effect of antisense oligonucleotides phosphorthioate on gene expression of TIMP-1 in rat liver fibrosis. World J Gastroenterol 2001; 7: 363-369.
16. Boeker KH, Haberkorn CI, Michels D, Flemming P, Manns MP, Lichtinghagen R. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta 2002; 316: 71-81.
17. Böker KH, Pehle B, Steinmetz C, Breitenstein K, Bahr M, Lichtinghagen R. Tissue inhibitors of metalloproteinases in liver and serum/plasma in chronic active hepatitis C and HCV-induced cirrhosis. Hepatogastroenterology 2000; 47: 812-819.
18. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Gan Zang Bing Za Zhi 2011; 19: 13-24 (in Chinese).
19. Menghini G. One-second needle biopsy of the liver. Gastroenterology 1958; 35: 190-199.
20. Chinese Society of Infectious Disease and Parasitology and Chinese Society of Hepatology of Chinese Medical Association. The programme of prevention and cure for virus hepatitis. Zhonghua Gan Zang Bing Za Zhi 2000; 8: 324-329 (in Chinese).
21. Arthur MJ. Degradation of matrix proteins in liver fibrosis. Pathol Res Pract 1994; 190: 825-833.
22. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5: 2145-2154.
23. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115: 3719-3727.
24. Vaillant B, Chiaramonte MG, Cheever AW, Soloway PD, Wynn TA. Regulation of hepatic fibrosis and extracellular matrix genes by the Th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J Immunol 2001; 167: 7017-7026.
25. Nie QH, Cheng YQ, Xie YM, Zhou YX, Bai XG, Cao YZ. Methodologic research on TIMP-1, TIMP-2 detection as a new diagnostic index for hepatic fibrosis and its significance. World J Gastroenterol 2002; 8: 282-287.
26. Jin Z, Sun R, Wei H, Gao X, Chen Y, Tian Z. Accelerated liver fibrosis in hepatitis B virus transgenic mice: involvement of natural killer T cells. Hepatology 2011; 53: 219-229.
27. Heymans S, Schroen B, Vermeersch P etal. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 2005; 112: 1136-1144.
28. Nee LE, McMorrow T, Campbell E, Slattery C, Ryan MP. TNF-alpha and IL-1beta-mediated regulation of MMP-9 and TIMP-1 in renal proximal tubular cells. Kidney Int 2004; 66: 1376-1386.
29. Ruiz V, Ordóñez RM, Berumen J etal. Unbalanced collagenases/TIMP-1 expression and epithelial apoptosis in experimental lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2003; 285: L1026-1036.
30. Albayrak A, Uyanik MH, Cerrah S etal. Is HMGB1 a new indirect marker for revealing fibrosis in chronic hepatitis and a new therapeutic target in treatment? Viral Immunol 2010; 23: 633-638.
31. Weng HL, Liu Y, Chen JL etal. The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis. Hepatology 2009; 50: 230-243.
32. Kiki I, Yilmaz O, Erdem F, Gundogdu M, Demircan B, Bilici M. Tumour necrosis factor-alpha levels in hepatitis B virus-related chronic active hepatitis and liver cirrhosis and its relationship to Knodell and Child-Pugh scores. Int J Clin Pract 2006; 60: 1075-1079.
33. Lu LG, Zeng MD, Wan MB etal. Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters. World J Gastroenterol 2003; 9: 2574-2578.